Charles Kim, MD
Urology · Honolulu, HINPI 1801823398
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,569 of the $9,212 with a category attached, or 60.4%. 21 manufacturers reported payments, led by Angiodynamics, Inc. at 47.2% of the total. 2025 is the largest year on record at $4,987, 5.0 times the $994 reported in 2019. Among urology clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $115.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$4K
- Astellas Pharma US Inc$890
- Boston Scientific$777
- Janssen Scientific Affairs, LLC$419
- Neotract Inc.$401
- Pfizer$333
- plus $2K from 15 others
What the payments were for
- Travel & lodging$3,39937%
- Food & beverage$5,56960%
- Education$2453%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 17 | $4,353 |
| Astellas Pharma US Inc | 8 | $890 |
| Boston Scientific | 14 | $777 |
| Janssen Scientific Affairs, LLC | 5 | $419 |
| Neotract Inc. | 4 | $401 |
| Pfizer | 4 | $333 |
| EMD Serono, Inc. | 3 | $296 |
| Intuitive Surgical | 4 | $274 |
| Teleflex LLC | 4 | $268 |
| Johnson & Johnson | 2 | $235 |
| Calyxo, Inc. | 1 | $173 |
| Histosonics, Inc. | 1 | $172 |
| Procept Biorobotics Corporation | 4 | $134 |
| AstraZeneca | 1 | $125 |
| Endo Pharmaceuticals Inc. | 1 | $122 |
| Heron Therapeutics, Inc. | 1 | $122 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $36 |
| Medtronic | 1 | $25 |
| Bayer | 1 | $24 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| Immunitybio, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$3,891
- XTANDI$699
- Erleada$338
- UroLift$288
- Da Vinci Surgical System$183
- GENERAL KIDNEY STONE DISEASE$175
- CVAC Aspiration System$173
- BAVENCIO$125
- LYNPARZA$125
- PADCEV$124
- XIAFLEX$122
- Zynrelef$122
- ZYTIGA$114
- TALZENNA$104
How this compares
$9,212 in reported general payments places this provider in the 90th percentile of 46 urology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 46 | $544,754 |
| Abiraterone Acetate | 66 | $221,418 |
| MyrbetriqMirabegron | 85 | $102,278 |
| OrgovyxRelugolix | 11 | $29,342 |
| Tamsulosin Hcl | 1,202 | $28,712 |
| Finasteride | 981 | $26,284 |
| GemtesaVibegron | 19 | $21,117 |
| Potassium Citrate ErPotassium Citrate | 163 | $15,350 |
| Terazosin Hcl | 259 | $5,760 |
| Dutasteride | 72 | $4,690 |
| Trimethoprim | 64 | $3,293 |
| Oxybutynin Chloride ErOxybutynin Chloride | 64 | $3,221 |
| Bicalutamide | 53 | $2,987 |
| Silodosin | 11 | $2,024 |
| Testosterone | 24 | $1,962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $890 | $647,032131 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $419 | $221,41866 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 46 urology providers in Hawaii.
Other urology in Honolulu
- Sergei TikhonenkovHonolulu$22K
- Timur RoytmanHonolulu$22K
- Robert CarlileHonolulu$10K
- David WeiHonolulu$9K
- Andrew SunHonolulu$9K
- Garry PeersHonolulu$8K
- Steve RiveraHonolulu$7K
- Tom FengHonolulu$6K
- Richard TsouHonolulu$5K
- Stephen ChinnHonolulu$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.